Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06150599 · ClinicalTrials.gov registry record · NA

Sacral Neuromodulation for Chronic Pelvic Pain

A NA study of Chronic Pelvic Pain Syndrome, sponsored by Corewell Health East.

Recruiting
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT06150599 is a NA study of Chronic Pelvic Pain Syndrome that is actively recruiting participants, run by Corewell Health East. The registered enrollment target is 25 participants, below the 194-participant average among 11 other Chronic Pelvic Pain Syndrome trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06150599, a NA study of Chronic Pelvic Pain Syndrome, is actively recruiting participants, sponsored by Corewell Health East.

RECRUITING
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.

Interventions

  • DEVICE Sacral neuromodulation

Study Locations (1)

Michigan

  • Corewell Health William Beaumont University Hospital - Royal Oak

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2025-06-30
Est. Completion 2028-12-01
Phase NA

Sponsor

Corewell Health East

106 total trials

What the Registry Record Tells You About NCT06150599

The ClinicalTrials.gov registry entry for NCT06150599 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 11 other Chronic Pelvic Pain Syndrome trials with a reported enrollment target (87% lower). The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Pelvic Pain Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Sacral neuromodulation is the first listed.

NCT06150599 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT06150599 about?

NCT06150599 is a clinical study titled "Sacral Neuromodulation for Chronic Pelvic Pain". Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelv...

What is the current status of trial NCT06150599?

This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2025-06-30. Estimated completion is 2028-12-01.

What conditions does trial NCT06150599 study?

This clinical trial studies the following conditions: Chronic Pelvic Pain Syndrome.

What interventions are being tested in trial NCT06150599?

The interventions under investigation include: Sacral neuromodulation (DEVICE).

Who is sponsoring clinical trial NCT06150599?

This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06150599 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pelvic Pain Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.